View Post

How to Navigate Metastatic Breast Cancer Test Results

In In The News by Barbara Jacoby

From: healthline.com Metastatic breast cancer (MBC), also called stage 4 or advanced breast cancer, means that breast cancer has spread beyond the breast and nearby lymph nodes to other organs in the body, like the bones or brain. Not all breast cancers are the same. If you’ve already received an MBC diagnosis, your doctor will most likely perform additional tests …

View Post

Fulvestrant Deemed Effective as Later-Line Breast Cancer Treatment

In In The News by Barbara Jacoby

Source: Conference Coverage From: cancertherapyadvisor.com Fulvestrant was found to be effective as an early and later-line treatment for women with hormone refractory metastatic breast cancer, according to the results of a retrospective study reported at the 17th St. Gallen International Breast Cancer Conference 2021. To conduct the study, researchers reviewed the medical records of women with hormone receptor-positive metastatic breast …

View Post

Savvy Cooperative: Paid Opportunity for Locally Advanced or Metastatic Pancreatic Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

SCREENER Eligibility Criteria: Adults who have been diagnosed with pancreatic cancer Verification of diagnosis will be required to participate Ages 18 years or older Have experienced symptoms in the past 30 days Currently living in the United States Able to read, write, and speak in English Details: 60-minute interview From a home computer Receive: $100 Link: https://gigs.savvy.coop/pancreatic-c/?r=44951 Why Sign Up? …

View Post

CONTESSA Trial Yields Positive Results for Patients with HER2-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA study of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer. New data suggests that a …

View Post

Allarity Therapeutics Begins European Study of Ixempra for Biomarker-Selected Breast Cancer Patients

In Clinical Studies News by Barbara Jacoby

By: Staff Reporter From: precisiononcologynews.com Allarity Therapeutics on Thursday said that it has enrolled the first patient in a European Phase II clinical trial evaluating the microtubulin inhibitor ixabepilone (Ixempra) as a third-line treatment for certain metastatic breast cancers. Specifically, Allarity — previously named Oncology Venture — will evaluate the agent, a product for which it in-licensed the European rights …

View Post

Understanding the Difference Between Invasive and Metastatic Breast Cancer

In In The News by Barbara Jacoby

From: healthline.com Understanding Abnormal Cells Abnormal cells aren’t cancerous, but they may increase your risk of developing cancer. When you have atypical cells that haven’t spread, the cells are considered noninvasive. This is sometimes referred to as pre-cancer or stage 0 cancer. Ductal carcinoma in situ (DCIS) is an example of this. DCIS is a noninvasive breast cancer of the …

View Post

Life-extending drug for incurable breast cancer approved for NHS use

In In The News by Barbara Jacoby

By: Denis Campbell From: theguardian.com About 3,300 women a year may benefit from decision to approve ribociclib Women with incurable advanced breast cancer will be able to get a drug from the NHS that can potentially extend their life by almost eight months, under new guidance. The National Institute for Health and Care Excellence (Nice) has approved the drug – …

View Post

Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE)

In Clinical Studies News by Barbara Jacoby

From: thelancet.com A multicentre, open-label, randomised, controlled, phase 3 trial Background Despite therapeutic advances in HER2-positive metastatic breast cancer, resistance to trastuzumab inevitably develops. In the PHOEBE study, we aimed to assess the efficacy and safety of pyrotinib (an irreversible pan-HER inhibitor) plus capecitabine after previous trastuzumab. Methods This is an open-label, randomised, controlled, phase 3 trial done at 29 …

View Post

Examining resistance to breast cancer treatments

In Clinical Studies News by Barbara Jacoby

By: Molly Chiu From: bcm.edu The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, a subset of patients will have tumors with intrinsic resistance to this therapy and most patients will develop resistant disease at some point during treatment. Researchers at the Lester …

View Post

Obesity ‘Clearly’ Not Tied to Worse Survival in MBC

In In The News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com First Large Cohort Study The relationship between obesity and overweight and breast cancer has some elements of mystery. But this is not one of them: in metastatic breast cancer (MBC), excess body weight does not negatively influence outcomes. Multiple small studies have demonstrated this point, and now, for the first time, a large multicenter cohort …